ArticleJournal of translational medicine2026
A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with limited therapeutic options in the relapsed or refractory setting. Selinexor, a selective inhibitor of nuclear export targeting XPO1, has demonstrated clinical activity in DLBCL. However, the molecular mechanisms underlying its antitumor effects remain incompletely defined.
methodsWe evaluated the clinical efficacy of Selinexor in a real-world cohort of lymphoma patients and performed integrative transcriptomic and proteomic analyses in DLBCL cell models representing germinal center B-cell–like (GCB) and non-GCB subtypes. Multi-omics profiling, pathway enrichment analysis, and targeted validation were used to characterize Selinexor-induced molecular alterations.
resultsSelinexor demonstrated meaningful clinical activity in DLBCL patients. Integrated multi-omics analyses revealed two principal mechanistic programs induced by XPO1 inhibition. First, Selinexor activated a p53-centered transcriptional network, characterized by suppression of key S-phase regulators, including GTSE1, PCNA, PCLAF, and CKS1B, leading to cell-cycle arrest and apoptosis. Second, Selinexor induced a metabolic stress response through downregulation of critical metabolic regulators such as SLC1A5 and RRM2, thereby restricting amino acid uptake and nucleotide biosynthesis. Notably, subtype-specific pathway coordination was observed: GCB models exhibited reciprocal regulation between p53 signaling and metabolic pathways, whereas non-GCB models displayed coordinated pathway activation.
conclusionsThese findings demonstrate that Selinexor exerts antitumor effects in DLBCL through concurrent activation of p53-mediated tumor suppression and disruption of metabolic homeostasis. The observed subtype-dependent pathway interactions provide mechanistic insight into Selinexor response and suggest potential opportunities for subtype-oriented therapeutic strategies.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.